Watch DNA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
44
WATCH · insiders 50, shorts 38
Insiders, 90 days
−$2K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $442.8MP/E —DIV YIELD —FCF YIELD -39.48%REV TTM $111.9M −46.8%NET INCOME −$290.8MNET CASH —52W 5.48 – 16.14SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $20.2M | −48.5% | 91.5% | −$58.5M | −$46.7M | — | -0.75 | −$44.3M | $2.6M | −$46.9M | Aug 6 |
| Q1 2026 · Mar 31 | $19.5M | −49.1% | 84.1% | −$71.4M | −$82.6M | — | -1.39 | −$46.7M | $1.9M | −$48.6M | May 7 |
| Q4 2025 · Dec 31derived | $33.4M | −23.8% | — | −$70.8M | −$80.8M | — | -1.42 | −$47.7M | $5K | −$47.7M | Feb 26 |
| Q3 2025 · Sep 30 | $38.8M | −56.4% | — | −$90M | −$80.8M | — | -1.45 | −$31.6M | $0 | −$31.6M | Nov 6 |
| Q2 2025 · Jun 30 | $39.1M | −30.4% | 86.3% | −$58.2M | −$60.3M | — | -1.10 | −$40.3M | $38K | −$40.3M | Aug 6 |
| Q1 2025 · Mar 31 | $38.2M | +0.8% | 89.3% | −$81M | −$91M | — | -1.68 | −$51.5M | $7.6M | −$59.1M | May 7 |
| Q4 2024 · Dec 31derived | $43.8M | +26.2% | — | −$103.6M | −$107.5M | — | -1.96 | −$42.4M | $13.7M | −$56.1M | Feb 26 |
| Q3 2024 · Sep 30 | $89M | +60.6% | — | −$55.2M | −$56.4M | — | -1.08 | −$103.5M | $15.1M | −$118.6M | Nov 6 |
| Q2 2024 · Jun 30 | $56.2M | — | — | −$222.9M | −$217.2M | — | -4.23 | −$84.4M | $27M | −$111.4M | Aug 7 |
| Q1 2024 · Mar 31 | $37.9M | — | — | −$178M | −$165.9M | — | -3.32 | −$89.3M | $6.7M | −$96M | May 6 |
| Q4 2023 · Dec 31derived | $34.8M | — | — | −$178.1M | −$211.7M | — | -4.28 | −$57.8M | $3.4M | −$61.3M | Feb 26 |
| Q3 2023 · Sep 30 | $55.4M | — | — | −$286.4M | −$302.9M | — | -6.21 | −$73.6M | $4.4M | −$77.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $170.2M | — | −$315.3M | −$312.8M | -183.8% | -5.64 | −$171.1M | $7.7M | −$178.7M | — | — |
| FY2024 · to Dec 31 | $227M | — | −$559.8M | −$547M | -240.9% | -10.54 | −$319.6M | $62.5M | −$382.1M | — | — |
| FY2023 · to Dec 31 | $251.5M | — | −$864.4M | −$892.9M | -355.1% | -18.37 | −$295.5M | $40.8M | −$336.3M | — | — |
| FY2022 · to Dec 31 | $477.7M | — | −$2.2B | −$2.1B | -440.6% | -50.20 | −$252.2M | $52.3M | −$304.5M | — | — |
| FY2021 · to Dec 31 | $313.8M | — | −$1.8B | −$1.8B | -583.1% | -1.39 | −$253.8M | $56.5M | −$310.3M | — | — |
| FY2020 · to Dec 31 | $76.7M | — | −$137M | −$126.6M | -165.2% | -0.10 | −$135.8M | $57.8M | −$193.7M | — | — |
Every number comes from Ginkgo Bioworks Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.